Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557317 | 0.86 | PTPN1 (0.39) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL629672 | 0.83 | PTPN1 (0.60) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL629290 | 0.83 | PTPN1 (0.60) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL629291 | 0.83 | PTPN1 (0.60) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL4648799 | 0.81 | PTPN1 (0.38) | PTPN1 | |
| SCHEMBL629895 | 0.76 | PTPN1 (0.61) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL629924 | 0.75 | PTPN1 (0.57) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL27725115 | 0.73 | GRIN2D (0.42) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL629388 | 0.73 | PTPN1 (0.57) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL27745953 | 0.71 | GRIN2D (0.39) | PTPN1GRIN2DGRIN2AGRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008067527-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |